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Abstract
Background: Modified citrus pectin (MCP) is known for its anti-cancer effects and its ability to be absorbed and
circulated in the human body. In this report we tested the ability of MCP to induce the activation of human blood
lymphocyte subsets like T, B and NK-cells.
Methods: MCP treated human blood samples were incubated with specific antibody combinations and analyzed
in a flow cytometer using a 3-color protocol. To test functionality of the activated NK-cells, isolated normal
lymphocytes were treated with increasing concentrations of MCP. Log-phase PKH26-labeled K562 leukemic cells
were added to the lymphocytes and incubated for 4 h. The mixture was stained with FITC-labeled active form of
caspase 3 antibody and analyzed by a 2-color flow cytometry protocol. The percentage of K562 cells positive for
PKH26 and FITC were calculated as the dead cells induced by NK-cells. Monosaccharide analysis of the MCP was
performed by high-performance anion-exchange chromatography with pulse amperometric detection (HPAEC-
PAD).
Results: MCP activated T-cytotoxic cells and B-cell in a dose-dependent manner, and induced significant dose-
dependent activation of NK-cells. MCP-activated NK-cells demonstrated functionality in inducing cancer cell death.
MCP consisted of oligogalacturonic acids with some containing 4,5-unsaturated non-reducing ends.
Conclusions: MCP has immunostimulatory properties in human blood samples, including the activation of
functional NK cells against K562 leukemic cells in culture. Unsaturated oligogalacturonic acids appear to be the
immunostimulatory carbohydrates in MCP.
Background
Pectin is a complex carbohydrate soluble fiber. Dietary
fibers, such as pectin, have been shown to have positive
effects on a wide spectrum of pathological conditions.
Their positive influence on human health is explained
by their anti-oxidative, hypocholesterolemic, and anti-
cancer effects [1-12]. The effect on the immune system
has been previously attributed to the down regulation of
the inflammatory response, moderating the production
of pro inflammatory cytokines and immunoglobulins in
murine models for irritable bowel syndrome [13]. A diet
rich in soluble fiber in an animal model showed protec-
tion against endotoxin-induced sickness behavior by
cytokine modulation and promotion of alternative acti-
vation of macrophages [14]. Citrus pectin has the capa-
city to exert a favourable immunomodulatory response
in human peripheral blood cells through its effect on
cytokine production [15]. High methoxy citrus pectin
inhibits the binding of fibroblast growth factor-1
(FGF-1) to its receptor in the presence of heparin [16].
The rhamnogalacturonan I-arabinan fraction of pectin
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colony-stimulating factor (G-CSF) by murine colonic
MCE 301 cells [17]. Rhamnogalacturonan I-arabinoga-
lactan was also reported to activate macrophages and
dendritic cells [18]. Methyl-esterified pectic oligosac-
charides with 4,5-unsaturated non-reducing ends
enhanced T-helper1 (Th1) dependent delayed-type
hypersensitivity in a murine influenza vaccine model,
reduced Th2 cytokine (IL-4, IL-5 and IL-10) production
in splenocytes in vitro [19] and decreased allergic
asthma in mice [20]. Therefore, the carbohydrate com-
position of pectin is very important in determining dif-
ferent immune responses.
The modified citrus pectin (MCP) used in this study,
is composed of short, slightly-branched, carbohydrate
chains derived from the soluble albedo fraction of citrus
fruit peels altered by decreasing the molecular weight
and degree of esterification using pH, temperature and a
controlled enzymatic process, in order to increase its
absorption into the circulatory system. MCP is relatively
rich in galactose, and antagonizes a binding protein
galectin-3 (Gal-3), which results in suppression of can-
cer cell aggregation, adhesion, and metastasis [5,6].
MCP acts as a ligand for Gal3, which plays a major role
in tumor formation and progression [12,21-24]. It has
been shown using a combination of fluorescence micro-
scopy, flow cytometry, and atomic force microscopy,
that specific binding of a pectin galactan to the recombi-
nant form of human galectin-3 has been physically
observed [25]. Moreover, MCP also showed anti-meta-
static effects on cancer cells in vitro or in vivo
[8,10,11,24,26-28]. Human clinical trials with MCP
showed an increase in prostate specific antigen doubling
time, a marker of slowing the progression of prostate
cancer [9], and significant improvement of quality of life
and stabilization of disease for patients with advanced
solid tumors [29]. Besides the therapeutic roles against
cancer, MCP has been shown to remove toxic metals
from the body [30,31], and reduce experimentally
induced kidney injury and fibrosis in vivo by reducing
galectin-3 levels [32]. In the United States of America,
MCP is registered as a food supplement and is generally
regarded as safe (GRAS).
In vitro lymphocyte activation represents a standard
approach for evaluating cell-mediated responses to a
variety of stimuli including immunostimulatory botani-
cal extracts. An appropriate assay system monitors the
expression of the early activation marker CD69 in whole
blood after stimulation with extracts. CD69 is expressed
in all activated lymphocyte subsets and hence it repre-
sents a generic marker to monitor individual subset
responses to specific stimuli [33]. CD4 antigen is
expressed on the T- helper/inducer lymphocyte subset
(CD3/CD4). CD8 antigen is expressed on the human
cytotoxic T-lymphocyte subset (CD3/CD8). Once acti-
vated both CD4 and CD8 positive T cells express CD69.
T-lymphocyte subsets can be identified and quantified
by using fluorochrome-labelled antibody combinations
such as CD4/CD69/CD3 and CD8/CD69/CD3. CD19
antigen is present on human B-lymphocytes at all stages
of maturation and is not present on resting or activated
T-lymphocytes. CD19/CD69/CD45 labelled antibody
combination can be used to identify an activated B cell
population. CD56 antigen is present on Natural Killer
(NK)-cells and antigen intensity increases with NK-cell
activation. Hence, CD56/CD69/CD45 labelled antibody
combination can be used to identify activated NK-cells.
The ability of NK-cell subset in normal lymphocytes to
induce death in leukemia cells is analyzed by co-incu-
bating MCP treated lymphocytes with K562 T-cell leu-
kemia cells. In this report we tested the ability of MCP
to induce the activation of human blood lymphocyte
subsets (T-helper/inducer, T-cytotoxic, B-cell, and NK-
cell), and the induced NK-cell’s activity against K562
chronic myeloid leukemia cells. Carbohydrate composi-
tion analysis was also performed to propose a structural
mechanism of action of this immune enhancement.
Methods
MCP (PectaSol-C
® MCP, Econugenics, Inc., Santa Rosa,
CA, USA) was initially solubilized in phosphate buffered
saline (PBS). The solubility of MCP in PBS was 76.4%.
The volume was adjusted to get accurate amounts of
the compound for treatment based on solubility factor.
T-, B- and NK-cell activation assay: Blood samples
were collected from three unidentified healthy volun-
teers based on an exempt study protocol submitted and
approved by the Miami Children’s Hospital Institutional
Review Board. Blood samples (250 μl) were incubated in
48-well plates with increasing concentrations of com-
pound along with appropriate positive controls (recom-
mended by Becton Dickinson Biosciences, CA, USA) for
each subset. CD2/CD2R and Phorbol ester (PMA) were
used as controls for T-cytotoxic cell activation studies.
Pokeweed (PWM) mitogen was used as positive control
for B-cell activation and IL-2 was used for activating
NK-cells in blood cultures. The blood cultures were
incubated at 37°C in a CO2 incubator for 24 h. On the
next day, 20 μl of specific antibody mix, [CD4-FITC/
CD69-PE/CD45-PerCP (T-helper/inducer cell activa-
tion), CD8-FITC/CD69-PE/CD3-PerCP (T-cytotoxic cell
activation), CD19-FITC/CD69-PE/CD45-PerCP (B-cell
activation) and CD56-FITC/CD69-PE/CD45-PerCP
(NK-cell activation)] was dispensed into separate flow
tubes (in duplicate) and 50 μl blood sample was mixed
with antibody and incubated for 30 min at room tem-
perature in the dark. The blood-antibody mix was lyzed
in a Coulter Epics Q-prep work station using
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ometer using a 3-color protocol. The percentage of acti-
vated T-helper cells, T-cytotoxic cells, B-cells and NK-
cells and the percentage increase over untreated control
were calculated and plotted against compound
concentrations.
Functional NK Cell Activity Assay: Normal lympho-
cytes were isolated from three healthy volunteers using
histopaque 1077 gradient centrifugation. The cells were
washed twice with PBS and re-suspended in phenol-free
RPMI 1640 medium supplemented with 10% fetal
bovine serum and antibiotics (complete medium). Cells
were plated in special 48-well deep plates (conical bot-
tom) at 10
6 cells/ml/well and treated with increasing
concentrations (0-800 ug/ml) of MCP in a 5% CO2
incubator at 37°C for 24 h. On the next day, log-phase
K562 leukemic cells were labelled with PKH26 mem-
brane dye (Sigma, St. Louis, MO, USA) for 5 min
according to manufacturer’s protocol and 0.2 × 10
6 cells
each were added to the normal lymphocytes in the 48
well plates. The plates were centrifuged for 1 min at 250
×ga n dr e t u r n e dt ot h eC O 2 incubator for another 4
hours for inducing cell death.
The cell mixture was permeabilized by incubating in
2% paraformaldehyde solution at 4°C followed by incu-
bation in 0.2% Tween 20 solution (PBS) at 37°C. The
cell mixture was washed with ice-cold PBS and stained
with human specific FITC-labeled active form of caspase
3 antibody for 30 minutes at room temperature accord-
ing to the procedure published earlier [34,35]. The
stained cells were washed with 0.1% Tween 20 solution,
resuspended in 0.5 ml of staining buffer and analyzed by
a two-color flow cytometry protocol with FL1 and FL2
measuring PKH26 and FITC, respectively in a Beckman
Coulter Elite Flow cytometer. The percentage of K562
cells positive for PKH26 and FITC are dead cells
induced by NK-cells.
Statistical Analysis: Mean and standard deviation
values were calculated and graphs prepared by Microsoft
Excel. Kruskal-Wallis one-way Analysis of Variance
(ANOVA) was used to analyze the data by the Graph-
Pad Prism 5 software and p values were estimated. Mul-
tiple comparisons of treatments in all possible
combinations were performed by Tukey-Kramer post
test using the GraphPad Prism 5 software.
Carbohydrate Composition Analysis of MCP: Mono-
saccharide analysis was performed by high-performance
anion-exchange chromatography with pulse ampero-
metric detection (HPAEC-PAD) following methanolysis
according previously published method [36]. HPAEC-
PAD was also used for oligosaccharide analysis [32].
Weight average intrinsic viscosity analysis was per-
formed by high-performance size-exclusion chromato-
graphy (HPSEC) with multiple detectors (multi-angle
laser light scattering, refractive index and differential
pressure viscometer according to previously publish
methods [30].
Results
T-Lymphocyte Subset Activation
The percent increases in T- helper/inducer lymphocyte
and T-cytotoxic cell activa t i o na r es h o w ni nF i g u r e1
&2, respectively. All positive controls induced expected
responses. Results show that MCP does not have a sig-
nificant effect on T-helper/inducer cell activation as
compared to positive controls like CD2/CD2R (p < 0.01)
and PMA (p < 0.001). However, MCP activated T-cyto-
toxic cells at lower levels and in a dose-dependent man-
ner between 50-800 ug/ml concentrations. MCP-
induced T-cytotoxic cell activation was significant at
400 ug/ml (p < 0.05) and highly significant at 800 ug/ml
(p < 0.01) concentrations.
B-Cell Activation
The percentage increase of MCP on B-cell activation
over untreated control is given in Figure 3. The positive
control PWM induced highly significant activation at 10
ug/ml (p < 0.01) and 25 ug/ml (p <0 . 0 0 1 )c o n c e n t r a -
tions. MCP induced a dose-dependent activation of B-
cells, although the level of activation was lower than
that of PWM and not significant by Tukey-Kramer test.
NK-Cell Activation
The effects of MCP on the percentage increase of NK-
cell activation over untreated control is given in Figure
4. The positive control IL-2 at 6.6 ng/ml induced a sig-
nificant level of NK-cell activation (p < 0.05). MCP
demonstrated a dose-dependent activation of NK-cells
with a lower significance level (p < 0.05) attained at 200
ug/ml and a highly significant level at 400 and 800 ug/
ml concentrations (p < 0.01).
MCP activated NK-Cell activity on K562 Chronic Myeloid
Leukemia Cells
The results of MCP-treated blood samples on increase
in percent of functional NK-cell activity is shown in
Figure 5. MCP induces NK-cell activity in a dose-depen-
dent manner with 800 ug/ml dose causing about 53.60%
increase in NK-cell activity (p < 0.05). The dose-depen-
dent increasing trend in NK-cell activity apparently cor-
responds with the activation of NK-cells obtained by
staining with NK-cell activation markers (CD56/CD69/
CD45).
MCP Carbohydrate Composition Analysis
The monosaccharide composition of the MCP was iden-
tified and is reported in Table 1. The MCP consisted of
mainly galacturonic acid with galactose and arabinose,
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Page 3 of 9the most common neutral sugars. The MCP had a high
amount of homogalacturonan compared to rhamnoga-
lacturonan (high GalA/Rha ratio). On average the
homogalacturonan backbone of the MCP was inter-
rupted with a rhamnose residue once every 22 galac-
turonic acid residues (Table 1). Arabinan, galactan or
arabinogalactan neutral sugar side-chains in pectin are
attached to the rhamnose residues in rhamnogalacturo-
nan. The homogalacturonan consisted of both saturated
and unsaturated oligogalacturonic acids (Figure 6). The
unsaturated oligogalacturonic acids had longer retention
times compared to saturated oligogalacturonic acids
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Figure 1 Increase in T-Helper/Inducer Cell activation (%) by MCP. (**p < 0.01, ***p < 0.001).
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Figure 2 Increase in T-Cytotoxic Cell activation (%) by MCP.( * p < 0.05, **p < 0.01).
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Page 4 of 9[36]. The MCP average molar mass (3,320 Da), average
intrinsic viscosity (0.0648 dL/g), and Mark Houwink
constant (a = 0.824) are reported (Table 2).
Discussion
The immune system protects people from disease caus-
ing microorganisms and other harmful materials. Circu-
lating blood transports immune components between
organs of the immune system and sites of inflammation.
The enumerative (activation marker assays) and func-
tional assays (NK cell activity assay) used in the present
study to evaluate the immunostimulative potential of
MCP clearly demonstrated activation of T cytotoxic and
NK cells in blood cultures in vitro. Furthermore, func-
tional assay indicated that MCP enhanced cytolysis of
leukemic cells by NK cells. It is well known that NK cell
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Figure 3 Increase in B-Cell activation (%) by MCP. (**p < 0.01, ***p < 0.001).
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Figure 4 Increase in NK-Cell activation (%) by MCP.( * p < 0.05, **p < 0.01).
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Page 5 of 9activity is regulated by the expression levels of cytotoxic
molecules, activating receptors and/or inhibitory recep-
tors. Even though several CAM agents have been shown
to activate NK-cells and improve NK cell activity, the
precise mechanism is not clearly defined. The two main
possibilities are: (i) augmentation of cytotoxic molecules
in NK cells and/or (ii) up-regulation of activating NK
receptors and/or down-regulation of inhibitory NK
receptors [37,38].
The mechanism for selective immunostimulation of T
cytotoxic and NK cells by MCP can only be speculated.
It is suggested that, except for a lower degree of esterifi-
cation, the MCP pectic oligosaccharide composition and
molecular weight is quite similar to other pectic oligo-
saccharides reported to polarize the T-helper response
toward Th1 in a murine influenza vaccination model
[19] and those used in subsequent studies of murine
allergic asthma [20] and human infant formula feeding
[39]. Therefore, unsaturated pectic oligosaccharides
appear to be required for immunostimulation and a
relatively high degree of esterification may be necessary
for stimulation of T-helper cells.
The average intrinsic viscosity of pectin is directly
proportional to the molar mass, thus demonstrating a
lower molecular weight range of the MCP compared to
14,800 Da and 0.398 dL/g reported previously [30]. The
lower Mark Houwink constant for MCP compared to
the 1.45 value that we observed previously [30] means
that the global structure has more random coil shape
typical of citrus pectin, while a higher Mark Houwink
constant (a) was interpreted as being more rigid and
rod like. Therefore, MCP is a flexible low molecular
weight pectin polymer enriched in saturated and unsatu-
rated oligogalacturonic acids.
MCP doses used previously in pre-clinical studies in
vivo (0.1% up to 4.0% orally administered) and human
clinical studies (15 grams/day orally administered) have
demonstrated an effect on both tumor growth, angio-
genesis, cancer progression markers, and spontaneous
metastasis [8-10,24,28,29] and the lowering of body bur-
den of heavy metals as seen in their blood and urinary
excretion levels [30,31]. These doses had an effect on
galectin-3 levels in experimentally induced kidney injury
which lead to reduced renal injury and fibrosis [32].
MCP concentrations used in the present investigation
(up to 0.08%) are below the previously used doses in
pre-clinical studies, which may be achievable and
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Figure 5 Increase in Percent NK-Cell activity by MCP. (*p < 0.05).
Table 1 MCP Monosaccharide Composition (Mole %)
Monosaccharide Mole %
Glucose 2.17
Arabinose 3.28
Galactose 10.31
Xylose 1.45
Rhamnose 3.53
Fructose 0.13
Galacturonic Acid 79.03
Glucuronic Acid 0.11
Galacturonic Acid/Rhamnose 22.39
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Figure 6 HPAEC-PAD analysis of MCP (1) compared to a polygalacturonic acid hydrolysate (2). The degree of polymerization is listed over
the peaks. The arrows point to unsaturated oligogalacturonic acids.
Table 2 MCP Average Molecular Weight, Intrinsic Viscosity and Shape Analysis (Mark Houwink Constant)
Average Molar Mass (Da) Average Intrinsic Viscosity (dL/g) Mark Houwink Constant (a)
3,320 ± 300 0.0648 ± 0.001 0.824 ± 0.03
Values are mean ± SD
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Page 7 of 9effective for modulation of immune system. However,
detailed pharmacokinetic investigations of MCP by ana-
lysing the in vivo absorption and distribution are
required to determine its effective oral dosage.
Conclusions
T h ed a t as h o w sM C Pa sas u b s t a n c ew i t hi m m u n o s t i -
mulatory properties in human blood samples, including
the activation of functional NK cells against K562 leuke-
mic cells in culture. The selective immunostimulatory
properties are proposed to be attributed to the presence
of low degree of methyl esterification and unsaturated
oligogalacturonic acids. Additional research is necessary
to determine if changing the degree of esterification of
oligogalactouronic acid in MCP can alter the immune
response. In vivo studies are necessary to better under-
stand the applications of MCP as an immune enhancer.
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